IKBKB-DT and lung carcinoma: Our observations therefore point to ALAL-1 as a possible target for lung cancer therapies, suggesting that the in vivo inhibition of ALAL-1 could have a “double-hit” anti-tumor effect: on one hand, by decreasing the autonomous capacity of cells to survive and proliferate and, on the other hand, by promoting immune infiltration and response against the tumor.